OTCMKTS:PXYN

Praxsyn Competitors

$0.0008
0.00 (0.00 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.00
Now: $0.00
$0.00
50-Day Range N/A
52-Week Range
$0.00
Now: $0.00
$0.01
VolumeN/A
Average Volume947,533 shs
Market Capitalization$678,353.60
P/E RatioN/A
Dividend YieldN/A
Beta-1.34

Competitors

Praxsyn (OTCMKTS:PXYN) Vs. NSPX, BTHE, VVUSQ, IMUCD, CAPS, and WWHC

Should you be buying PXYN stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Praxsyn, including Inspyr Therapeutics (NSPX), Boston Therapeutics (BTHE), VIVUS (VVUSQ), ImmunoCellular Therapeutics (IMUCD), Capstone Therapeutics (CAPS), and W World (WWHC).

Praxsyn (OTCMKTS:PXYN) and Inspyr Therapeutics (OTCMKTS:NSPX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Earnings & Valuation

This table compares Praxsyn and Inspyr Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PraxsynN/AN/AN/AN/AN/A
Inspyr TherapeuticsN/AN/A$-930,000.00N/AN/A

Volatility & Risk

Praxsyn has a beta of -1.34, suggesting that its stock price is 234% less volatile than the S&P 500. Comparatively, Inspyr Therapeutics has a beta of -16.55, suggesting that its stock price is 1,755% less volatile than the S&P 500.

Profitability

This table compares Praxsyn and Inspyr Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PraxsynN/AN/AN/A
Inspyr TherapeuticsN/AN/A-298.11%

Analyst Recommendations

This is a summary of current ratings and target prices for Praxsyn and Inspyr Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Praxsyn0000N/A
Inspyr Therapeutics0000N/A

Summary

Praxsyn beats Inspyr Therapeutics on 2 of the 2 factors compared between the two stocks.

Praxsyn (OTCMKTS:PXYN) and Boston Therapeutics (OTCMKTS:BTHE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Volatility and Risk

Praxsyn has a beta of -1.34, suggesting that its stock price is 234% less volatile than the S&P 500. Comparatively, Boston Therapeutics has a beta of -0.16, suggesting that its stock price is 116% less volatile than the S&P 500.

Valuation & Earnings

This table compares Praxsyn and Boston Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PraxsynN/AN/AN/AN/AN/A
Boston Therapeutics$20,000.00111.13$-3,690,000.00N/AN/A

Praxsyn has higher earnings, but lower revenue than Boston Therapeutics.

Profitability

This table compares Praxsyn and Boston Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PraxsynN/AN/AN/A
Boston Therapeutics-24,627.27%N/A-3,480.61%

Analyst Ratings

This is a summary of current ratings and recommmendations for Praxsyn and Boston Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Praxsyn0000N/A
Boston Therapeutics0000N/A

VIVUS (OTCMKTS:VVUSQ) and Praxsyn (OTCMKTS:PXYN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Risk and Volatility

VIVUS has a beta of -3.25, meaning that its share price is 425% less volatile than the S&P 500. Comparatively, Praxsyn has a beta of -1.34, meaning that its share price is 234% less volatile than the S&P 500.

Institutional and Insider Ownership

7.3% of VIVUS shares are owned by institutional investors. 12.0% of VIVUS shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares VIVUS and Praxsyn's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VIVUS$69.76 million0.03$-31,500,000.00($2.96)-0.04
PraxsynN/AN/AN/AN/AN/A

Praxsyn has lower revenue, but higher earnings than VIVUS.

Profitability

This table compares VIVUS and Praxsyn's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
VIVUS-39.28%N/A-12.18%
PraxsynN/AN/AN/A

Analyst Recommendations

This is a breakdown of current recommendations for VIVUS and Praxsyn, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
VIVUS0000N/A
Praxsyn0000N/A

ImmunoCellular Therapeutics (OTCMKTS:IMUCD) and Praxsyn (OTCMKTS:PXYN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Analyst Recommendations

This is a breakdown of current recommendations for ImmunoCellular Therapeutics and Praxsyn, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunoCellular Therapeutics0000N/A
Praxsyn0000N/A

Volatility and Risk

ImmunoCellular Therapeutics has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Comparatively, Praxsyn has a beta of -1.34, suggesting that its share price is 234% less volatile than the S&P 500.

Earnings & Valuation

This table compares ImmunoCellular Therapeutics and Praxsyn's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoCellular TherapeuticsN/AN/A$-14,310,000.00N/AN/A
PraxsynN/AN/AN/AN/AN/A

Profitability

This table compares ImmunoCellular Therapeutics and Praxsyn's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunoCellular TherapeuticsN/AN/AN/A
PraxsynN/AN/AN/A

Summary

ImmunoCellular Therapeutics beats Praxsyn on 1 of the 1 factors compared between the two stocks.

Praxsyn (OTCMKTS:PXYN) and Capstone Therapeutics (OTCMKTS:CAPS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability.

Institutional & Insider Ownership

2.6% of Capstone Therapeutics shares are owned by institutional investors. 42.8% of Capstone Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Praxsyn and Capstone Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Praxsyn0000N/A
Capstone Therapeutics0000N/A

Volatility and Risk

Praxsyn has a beta of -1.34, meaning that its stock price is 234% less volatile than the S&P 500. Comparatively, Capstone Therapeutics has a beta of 176.15, meaning that its stock price is 17,515% more volatile than the S&P 500.

Valuation & Earnings

This table compares Praxsyn and Capstone Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PraxsynN/AN/AN/AN/AN/A
Capstone Therapeutics$2 million0.97$-380,000.00N/AN/A

Praxsyn has higher earnings, but lower revenue than Capstone Therapeutics.

Profitability

This table compares Praxsyn and Capstone Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PraxsynN/AN/AN/A
Capstone TherapeuticsN/AN/AN/A

Summary

Capstone Therapeutics beats Praxsyn on 4 of the 4 factors compared between the two stocks.

Praxsyn (OTCMKTS:PXYN) and W World (OTCMKTS:WWHC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, institutional ownership, risk and profitability.

Valuation & Earnings

This table compares Praxsyn and W World's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PraxsynN/AN/AN/AN/AN/A
W WorldN/AN/AN/AN/AN/A

Profitability

This table compares Praxsyn and W World's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PraxsynN/AN/AN/A
W WorldN/AN/AN/A

Volatility and Risk

Praxsyn has a beta of -1.34, meaning that its stock price is 234% less volatile than the S&P 500. Comparatively, W World has a beta of 1.97, meaning that its stock price is 97% more volatile than the S&P 500.

Institutional & Insider Ownership

0.1% of W World shares are owned by institutional investors. 61.1% of W World shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Praxsyn and W World, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Praxsyn0000N/A
W World0000N/A

Summary

W World beats Praxsyn on 3 of the 3 factors compared between the two stocks.


Praxsyn Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
NSPX
Inspyr Therapeutics
0.5$0.02flat$2.34 millionN/A0.00Gap Down
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.02flat$2.22 million$20,000.00-1.00
VVUSQ
VIVUS
0.6$0.12flat$2.10 million$69.76 million-0.04
IMUCD
ImmunoCellular Therapeutics
0.0$0.48flat$2.01 millionN/A0.00
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$36.01flat$1.95 million$2 million0.00High Trading Volume
Gap Down
WWHC
W World
0.8$6.09flat$1.80 millionN/A0.00Increase in Short Interest
News Coverage
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.03flat$1.70 million$530,000.000.00Gap Down
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.48flat$1.69 millionN/A0.00
Cardax logo
CDXI
Cardax
0.0$2.10flat$1.67 million$710,000.000.00
MLNTQ
Melinta Therapeutics
0.2$0.11flat$1.51 million$96.43 million0.00
Achaogen logo
AKAOQ
Achaogen
0.6$0.03flat$1.31 million$8.73 million0.00Gap Up
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05flat$1.12 millionN/A-0.57Decrease in Short Interest
News Coverage
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04flat$1.11 millionN/A0.00Gap Up
AOXG
Aoxing Pharmaceutical
0.5$0.01flat$1.05 millionN/A0.00
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.22flat$1.03 millionN/A0.00Decrease in Short Interest
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07flat$970,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
SPHS
Sophiris Bio
0.1$0.03flat$963,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
AOLS
Aeolus Pharmaceuticals
0.8$0.01flat$928,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
ATRX
Adhera Therapeutics
0.0$0.08flat$872,000.00$250,000.000.00
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.02flat$772,000.00N/A0.00
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.03flat$749,000.00N/A0.00News Coverage
Gap Up
SKVI
Skinvisible
0.7$0.15flat$671,000.00$40,000.000.00
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05flat$572,000.00$1.90 million0.00
TRPXD
Therapix Biosciences
0.0$9.15flat$458,000.00N/A0.00High Trading Volume
BSPM
Biostar Pharmaceuticals
0.0$0.17flat$436,000.00N/A0.00
HSTC
HST Global
0.8$0.07flat$378,000.00N/A0.00
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.02flat$374,000.00N/A0.00Increase in Short Interest
Gap Down
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47flat$338,000.00$36.55 million0.00News Coverage
Gap Up
PZRXQ
PhaseRx
0.2$0.03flat$298,000.00N/A0.00Decrease in Short Interest
News Coverage
WDBG
Woodbrook Group
0.0$1.60flat$224,000.00N/A0.00
ROSGQ
Rosetta Genomics
0.0$0.09flat$124,000.00N/A0.00Gap Down
MetaStat logo
MTST
MetaStat
0.0$0.02flat$118,000.00$20,000.000.00
OREXQ
Orexigen Therapeutics
0.4$0.01flat$100,000.00$33.71 million0.00Gap Up
AXMP
AXM Pharma
0.2$0.00flat$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00flat$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00flat$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.02flat$9,000.00$110,000.000.00Decrease in Short Interest
Gap Down
Acusphere logo
ACUS
Acusphere
0.0$0.03flat$0.00N/A0.00Gap Up
Affymax logo
AFFY
Affymax
0.6$0.09flat$0.00N/A0.00Gap Down
AOBI
American Oriental Bioengineering
0.4$1.50flat$0.00N/A0.00
ARYX
ARYx Therapeutics
0.0$0.01flat$0.00N/A0.00Gap Down
AHROQ
AtheroNova
0.0$0.01flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.07flat$0.00N/A0.00Gap Up
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.01flat$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.49flat$0.00$9.93 million8.13
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00
FTCY
Global Future City
0.5$0.00flat$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$35.08flat$0.00N/A0.00Decrease in Short Interest
News Coverage
Gap Down
HRBR
Harbor Diversified
0.0$1.16flat$0.00$263.61 million0.00
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.